Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

The accelerated approval was based on data from the phase 1/2 BRUIN trial that included a subset of 108 patients with CLL/SLL. The Food and Drug Administration (FDA) has granted accelerated approval ...

Understanding the diagnosis and treatment options empowered the patient, fostering a sense of control and preparedness. Maintaining a positive mental attitude and aligning with supportive healthcare ...

BGB-16673, a BTK degrader, targets relapsed/refractory CLL/SLL, showing promising efficacy in heavily pretreated patients. The FDA's fast track designation aims to expedite drug development for ...

Eli Lilly LLY announced that the FDA has expanded the label of its BTK inhibitor drug, Jaypirca (pirtobrutinib), in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indications.

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center ...

Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib ...